CRISPR Therapeutics AG (CRSP) Long-Term Debt Issuances (2016 - 2026)

CRISPR Therapeutics AG (CRSP) posted Long-Term Debt Issuances of $600.0 million for Q1 2026, up 5999900.0% sequentially from $10000.0 in Q4 2016.

CRISPR Therapeutics AG (CRSP) Long-Term Debt Issuances (2016 - 2026) Analysis & Trends

CRISPR Therapeutics AG has reported Long-Term Debt Issuances for 2 years, with the latest figure at $600.0 million in Q1 2026.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $600.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $600.0 million (up 6000000.0% YoY) and the FY2016 annual result came in at $35.0 million, down 8.44% from the prior year.
Long-Term Debt Issuances advanced to $600.0 million in Q1 2026 per CRSP's latest filing, from $10000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $600.0 million in Q1 2026 and troughed at $600.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-675,522.58
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	CRISPR Therapeutics AG	5.18 Bn	5.18 Bn	-	-

Download Data